Sunflower Pharmaceuticals Group Co Ltd (SHE:002737) — Market Cap & Net Worth
Market Cap & Net Worth: Sunflower Pharmaceuticals Group Co Ltd (002737)
Sunflower Pharmaceuticals Group Co Ltd (SHE:002737) has a market capitalization of $961.40 Million (CN¥6.57 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9141 globally and #2269 in its home market, demonstrating a -2.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sunflower Pharmaceuticals Group Co Ltd's stock price CN¥11.25 by its total outstanding shares 584000000 (584.00 Million). Also see Sunflower Pharmaceuticals Group Co Ltd assets under control for a full breakdown of the balance sheet.
Sunflower Pharmaceuticals Group Co Ltd Market Cap History: 2015 to 2026
Sunflower Pharmaceuticals Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.47 Billion to $961.40 Million (-3.39% CAGR). Also see Sunflower Pharmaceuticals Group Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Sunflower Pharmaceuticals Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sunflower Pharmaceuticals Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Sunflower Pharmaceuticals Group Co Ltd (002737) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.54x
Sunflower Pharmaceuticals Group Co Ltd's market cap is 0.54 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.05 Billion | $3.36 Billion | $303.02 Million | 0.31x | 3.46x |
| 2017 | $967.87 Million | $3.86 Billion | $424.00 Million | 0.25x | 2.28x |
| 2018 | $951.86 Million | $4.47 Billion | $563.28 Million | 0.21x | 1.69x |
| 2019 | $1.01 Billion | $4.37 Billion | $565.42 Million | 0.23x | 1.78x |
| 2020 | $1.07 Billion | $3.46 Billion | $584.45 Million | 0.31x | 1.83x |
| 2021 | $1.23 Billion | $4.46 Billion | $704.74 Million | 0.28x | 1.74x |
| 2022 | $1.81 Billion | $5.09 Billion | $867.22 Million | 0.35x | 2.08x |
| 2023 | $2.11 Billion | $5.70 Billion | $1.12 Billion | 0.37x | 1.88x |
| 2024 | $1.75 Billion | $3.38 Billion | $492.05 Million | 0.52x | 3.56x |
| 2025 | $1.26 Billion | $2.32 Billion | -$257.83 Million | 0.54x | N/A |
Competitor Companies of 002737 by Market Capitalization
Companies near Sunflower Pharmaceuticals Group Co Ltd in the global market cap rankings as of September 19, 2026. Review 002737 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sunflower Pharmaceuticals Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Sunflower Pharmaceuticals Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Sunflower Pharmaceuticals Group Co Ltd's market cap moved from $1.47 Billion to $ 961.40 Million, with a yearly change of -3.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥961.40 Million | -23.83% |
| 2025 | CN¥1.26 Billion | -27.92% |
| 2024 | CN¥1.75 Billion | -16.87% |
| 2023 | CN¥2.11 Billion | +16.52% |
| 2022 | CN¥1.81 Billion | +47.10% |
| 2021 | CN¥1.23 Billion | +14.73% |
| 2020 | CN¥1.07 Billion | +6.49% |
| 2019 | CN¥1.01 Billion | +5.67% |
| 2018 | CN¥951.86 Million | -1.65% |
| 2017 | CN¥967.87 Million | -7.61% |
| 2016 | CN¥1.05 Billion | -28.70% |
| 2015 | CN¥1.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Sunflower Pharmaceuticals Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $961.40 Million USD |
| MoneyControl | $961.40 Million USD |
| MarketWatch | $961.40 Million USD |
| marketcap.company | $961.40 Million USD |
| Reuters | $961.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines in China and internationally. It offers traditional Chinese medicines, chemical drugs, biological drugs, and health and wellness products, as well as adult and children's medicines for various therapeutic areas, including pediatrics, gynecology,… Read more